By Fineline Cube 
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug JKN2301 dry suspension. The drug is intended for the treatment of uncomplicated influenza A and B in children aged 2 to under 12 years.
Drug Formulation and Target Population
JKN2301 is specifically formulated as a dry suspension for pediatric use, allowing flexible dosage adjustments based on children’s body weight. This design aims to improve medication compliance and address the clinical needs of pediatric influenza treatment.
Market Context
According to sample statistical estimates, the domestic anti-influenza drug market reached approximately RMB 4.7 billion (USD 656 million) in sales in 2024.-Fineline Info & Tech